about
Microwave-Assisted Synthesis of Bioactive Six-Membered Heterocycles and Their Fused AnaloguesTargeting melanoma by small molecules: challenges aheadPersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceTargeted therapy using nanotechnology: focus on cancerInsights into the Conformational Variability and Regulation of Human Nek2 KinaseMathematical and computational modeling in biology at multiple scalesTranslational integrity and continuity: personalized biomedical data integrationOn/off-switchable anti-neoplastic nanoarchitectureIntegrated functional, gene expression and genomic analysis for the identification of cancer targetsIdentification of direct target engagement biomarkers for kinase-targeted therapeuticsA global comparison of the human and T. brucei degradomes gives insights about possible parasite drug targetsInhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsMicrofluidic cell isolation technology for drug testing of single tumor cells and their clusters.Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.Regioselective synthesis and biological studies of novel 1-aryl-3, 5-bis (het) aryl pyrazole derivatives as potential antiproliferative agents.Chemogenomics approaches to novel target discovery.A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I studyMethodological approaches in application of synthetic lethality screening towards anticancer therapyMethotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2A magnetic bead-based protein kinase assay with dual detection techniques.Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.Expression profiling in canine osteosarcoma: identification of biomarkers and pathways associated with outcome.Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.Guidelines for the welfare and use of animals in cancer research.The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.Integrated analysis identifies interaction patterns between small molecules and pathwaysProbing the probes: fitness factors for small molecule tools.Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification.A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genesA high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity.Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcomaDrugging the PI3 kinome: from chemical tools to drugs in the clinic.Lipid analysis of eight human breast cancer cell lines with ToF-SIMS.Advances in measuring single-cell pharmacology in vivo.Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cellsBiological rationale for the design of polymeric anti-cancer nanomedicines.
P2860
Q26752782-A5C83EBE-D1A0-42DB-B35B-0550F83E1A20Q26824642-425723BF-F3F4-41CA-9983-4A94E9C842C7Q26866517-2999F7FC-41A7-4D75-8013-2FD44136997EQ27023361-AE64DA1E-BFA6-4A07-A986-7665CBBB2969Q27653344-6A14ADDB-AA4B-4DCB-B439-6FDAC95BA2E7Q28082151-2527260E-C0A8-438F-9E07-5BCBC7E32FF9Q28388444-BDFC104B-4736-43EA-95C2-0CF41C77EAF7Q28389792-6E0975BA-2522-479C-807E-D8677022131BQ28475254-8F3B45AD-994C-4E6A-95D3-25653947703AQ28477593-A7855543-B003-4313-B3DC-7C3F637E1C17Q28485518-B3B6A06C-6EED-42D8-894D-313014F2E527Q28817295-0E88C0B6-116F-45B0-97B1-9054C6E01261Q30364122-619997CE-0D1A-4866-B08D-4241D2CDDCB5Q30381467-8D43F16E-A021-4816-9703-CE91EBF8D7F4Q32185870-8612A52B-6C51-4F7E-BA89-2F8E7D2388ECQ33286936-96247A50-3AC9-48BC-B31B-878EBE1303DEQ33294239-6BCAA994-3B6C-4FDD-80D0-934B8DF9F976Q33388272-7F532016-C554-4BA7-87DC-61568838C36BQ33421697-451F2DB0-CD51-4D8C-B9FE-359D4E079B30Q33521938-93984B6B-B4E2-478E-94BC-23C111AA9E1CQ33679500-3757332A-1834-426C-BD7D-3398EC1A931DQ33696408-18B5EA83-5738-418B-B13A-C8C4230E9372Q33699400-5B3EFF48-16DC-405A-B521-E2A93BB2D581Q33699594-0A4933F0-7788-4FAE-96F7-26CB089B0EB3Q33903753-4C1B12C2-BA9A-4704-B88C-F213B239E9ECQ33959529-ABC98BAD-633F-4D2D-A549-923BAB1F521FQ33975831-EBB073D4-76DE-4CC5-8A5D-A6911B83799AQ33999789-D8AFF8F8-6F3A-4DAF-9AD2-A60D4299EA61Q34001269-0CC8AA2A-BC66-45DB-8D1C-A614C27AAD66Q34470371-DA997067-F584-40C4-A8E7-6E13BED3F374Q35000701-263B62F5-8C97-4B72-8C41-C75D16524326Q35201777-3BE65355-3958-4091-B37C-E0A1925BEC93Q35570248-CEB17BE7-E702-45D8-A00C-6A944477B020Q35622141-9ECB7ECA-FDAC-467B-A1AC-79FAC375B636Q36004758-8EE81A44-CE51-47A6-A1D0-5F4F0B279B92Q36054366-9CA54403-18F6-44BE-B081-560FC7AD223AQ36100853-8DE0E926-E79E-46AD-A6EC-76C10EE7667DQ36108221-C5BDF691-3EDD-46F8-940A-969912178D5DQ36130906-A37CD398-0F16-4EC8-BF2D-23B0C290D258Q36160333-66865F45-298E-42EC-A3EC-407621C0652F
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
New approaches to molecular cancer therapeutics.
@ast
New approaches to molecular cancer therapeutics.
@en
type
label
New approaches to molecular cancer therapeutics.
@ast
New approaches to molecular cancer therapeutics.
@en
prefLabel
New approaches to molecular cancer therapeutics.
@ast
New approaches to molecular cancer therapeutics.
@en
P2860
P356
P1476
New approaches to molecular cancer therapeutics.
@en
P2093
Ian Collins
P2860
P2888
P304
P356
10.1038/NCHEMBIO840
P50
P577
2006-12-01T00:00:00Z